PLAG alleviates cisplatin-induced cachexia in lung cancer implanted mice

Area of Science:

• Oncology
• Biochemistry
• Pharmacology

Background:

• Chemotherapy-induced cachexia presents a major obstacle in cancer treatment, causing debilitating muscle loss, appetite reduction, and weight loss.
• Effective management of cachexia is crucial for improving patient tolerance to chemotherapy and overall treatment success.

Purpose of the Study:

• To investigate the efficacy of 1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol (PLAG) in alleviating chemotherapy-induced cachexia.
• To evaluate PLAG's impact on muscle mass, muscle fiber characteristics, inflammatory markers, and tumor growth in a preclinical model.

Main Methods:

• Tumor-implanted mice were treated with cisplatin to induce cachexia.
• Concurrent treatment with PLAG was administered to assess its protective effects.
• Measurements included body weight, muscle weight (quadriceps femoris, gastrocnemius), muscle fiber distribution and size, myostatin expression, inflammatory cytokines (TNF-α, IL-6), and glucose absorption.

Main Results:

• Cisplatin treatment led to significant weight loss, reduced feeding, and up to 70% reduction in major leg muscle mass.
• PLAG co-treatment successfully prevented muscle loss, restored muscle fiber morphology, and normalized myostatin expression.
• PLAG reduced elevated levels of tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) and improved glucose absorption, indicating restored muscle activity.
• PLAG also demonstrated a reduction in tumor growth.

Conclusions:

• 1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol (PLAG) effectively alleviates key symptoms of cisplatin-induced cachexia in a preclinical model.
• PLAG's multifaceted benefits include muscle preservation, anti-inflammatory effects, and improved metabolic function.
• These findings highlight PLAG as a potential therapeutic agent to mitigate cachexia in cancer patients receiving chemotherapy.